ACET

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Cytokine, PST, ASH, AUC, ACET, PD, Stem cell factor, Patient, CD19, Tmax, Allele, HLA, Cancer, Cmax, NHL, Pharmacodynamics, Investigator's brochure, Pharmaceutical industry, Vaccine, Medical imaging, Generic drug, Persistence

The data will be provided during a poster presentation at the ASH Annual Meeting on Sunday, December 10, 2023.

Key Points: 
  • The data will be provided during a poster presentation at the ASH Annual Meeting on Sunday, December 10, 2023.
  • “Historically, expansion and persistence of cell therapy products and release of functional cytokines have correlated with patient outcomes.
  • We remain on track to provide a clinical update from the Phase 1 study in NHL patients in the second half of 2024."
  • Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
    Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PST

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CAR, Trial of the century, IND, Food, Bio, CD70, Renal cell carcinoma, International Conference on Afghanistan, London (2010), CD20, Society for Immunotherapy of Cancer, Tropism, TGF, Conference, CDMO, Regulation of tobacco by the U.S. Food and Drug Administration, Prostate cancer, R, Engineering, Poster, Goodwill, SITC, Immunotherapy, MCL, Research and development, Annual general meeting, Probability, ACET, Tumor microenvironment, Epitope, NHL, Society, Cancer, PSMA, Patient, Administration, Prognosis, Prostate, CD27, Pharmaceutical industry, Cryptocurrency

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.
  • In October 2023, Adicet presented new preclinical data building on the potential of Adicet’s allogeneic gamma delta platform as a promising approach to target prostate cancer.
  • Financial Results for Third Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the three months ended September 30, 2023, compared to $16.6 million during the same period in 2022.
  • Cash Position: Cash and cash equivalents were $183.3 million as of September 30, 2023, compared to $257.7 million as of December 31, 2022.

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 7, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, ACET, Cancer, Conference, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.
  • Details of the event are as follows:
    The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com .
  • An archived replay will be available for 30 days following the presentation.

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, ASH, Pharmacodynamics, ACET, Patient, Cancer, PDT, Bio, American Society for Investigative Pathology, Society, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.
  • Details of the poster presentation are as follows:
    Title: Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
    Session Name: 704.
  • Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
    Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, ACET, Cancer, Employment, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023.
  • One individual was hired by Adicet in October 2023 and granted new hire non-qualified stock options to purchase 5,000 shares of Adicet’s common stock with an exercise price of $1.32 per share, the closing price of Adicet’s common stock as reported by Nasdaq on October 31, 2023.
  • The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023.
  • The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Retrieved on: 
Wednesday, October 4, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, European Organisation for Research and Treatment of Cancer, ACET, Bio, American Association for Cancer Research, National Cancer Institute, International Conference on Bioinformatics, Therapy, Conference, Treatment, Pharmaceutical industry, Paint, Cancer

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.
  • Details of the poster presentation is as follows:

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Genetics, Health, Oncology, Cancer, Employment, ACET, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on September 29, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on September 29, 2023.
  • Four individuals were hired by Adicet in September 2023.
  • In the aggregate, Adicet granted new hires non-qualified stock options to purchase 32,200 shares of Adicet’s common stock with an exercise price of $1.37 per share, the closing price of Adicet’s common stock as reported by Nasdaq on September 29, 2023.
  • The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Abstract, Society, ACET, Bio, SITC, Immunotherapy, EDT, CAR, Journal, JITC, Annual general meeting, Society for Immunotherapy of Cancer, Medical imaging, Cancer

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.
  • Details of the poster presentation are as follows:
    Abstract Title: Assay Development and Quantitative Detection of ADI-001, a CD20-Targeted γδ1 CAR T Therapy, using AlloCell, a Universal Assay for Monitoring of “Off-the-Shelf" Allogeneic Cell Therapies
    These abstracts will be available as a supplement in the Journal for ImmunoTherapy of Cancer (JITC) on Tuesday, October 31, 2023 at 9:00 a.m. EDT on www.sitcancer.org .

Octav Raises 2.65 Million To Help Label DeFi Transactions

Retrieved on: 
Saturday, September 16, 2023
Database, Nascent, ACET, AAVE, Mathieu, Intel Parallel Studio, Ecosystem, Playbook, Cryptocurrency, Decentralized finance, Octav

Octav , a DeFi labeling and tax reconciliation platform, raised a $2.65 million seed to help label the DeFi ecosystem and be the “Quickbooks of crypto”.

Key Points: 
  • Octav , a DeFi labeling and tax reconciliation platform, raised a $2.65 million seed to help label the DeFi ecosystem and be the “Quickbooks of crypto”.
  • “There hasn’t been a systematic way where the DeFi community can decipher all their transactions from block explorers and get their data in one convenient dashboard,” said Mathieu Baril, Co-Founder & CEO of Octav.
  • Octav is led by Mathieu Baril & Luc Blackburn , both of whom have previously worked at companies like Zapper, Accedian Network and Otodata before starting Octav.
  • “Octav is currently in beta with thousands of users, seven integrated chains, and over 100 million transactions indexed to date”, Mathieu said.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 31, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Employment, ACET, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on August 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on August 31, 2023.
  • Two individuals were hired by Adicet in August 2023.
  • In the aggregate, Adicet granted new hires non-qualified stock options to purchase 12,200 shares of Adicet’s common stock with an exercise price of $2.00 per share, the closing price of Adicet’s common stock as reported by Nasdaq on August 31, 2023.
  • The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).